US Material Events SEC 8-K Filings — August 14, 2026

14-08-2026

NightFood Holdings, Inc. (NGTF) announced board and executive changes effective August 7 and 10, 2026, as part of its NASDAQ listing application. Two directors resigned, three new independent directors were appointed, and standing board committees were established. Yury Pyatigorsky was appointed CFO, replacing Jimmy Chan, who remains CEO and Secretary. The company cautions there is no assurance it will meet NASDAQ listing qualifications.

• · Lei Sonny Wang and Thomas Morse resigned effective Aug. 7, 2026; neither resignation resulted from a disagreement.
• · Darren Kenney is a CPA and licensed California real estate broker; Ronald J. Stauber is an attorney with corporate governance and securities experience.
• · The board established three standing committees: Audit, Compensation, and Nominating/Corporate Governance/Compliance.
• · The company is doing business as TechForce Robotics and focuses on AI-powered enterprise robotics and automation.
• · The company cautions that there is no assurance it will meet NASDAQ listing qualifications or that NASDAQ will list the company.

14-08-2026

Proficient Auto Logistics, Inc. (PAL) announced the pricing of a $75.0 million convertible senior notes offering due 2033, with a 5.50% coupon and an initial conversion price of approximately $6.50 per share, representing a 27.5% premium over the $5.10 closing price on August 11, 2026. The company expects net proceeds of about $71.4 million, which will be used to refinance outstanding indebtedness and pay premiums on capped call transactions entered to reduce potential dilution. The notes are unsecured and will be offered privately to qualified institutional buyers, with settlement expected on August 13, 2026.

• · The notes mature on August 15, 2033, unless earlier repurchased, redeemed or converted.
• · Interest is payable semi-annually on February 15 and August 15, beginning February 15, 2027.
• · Before May 15, 2033, conversion is allowed only upon certain events; after that date, holders may convert at any time.
• · Proficient may settle conversions in cash, shares, or a combination thereof.
• · The initial conversion price of ~$6.50 per share represents a 27.5% premium over the $5.10 closing price on August 11, 2026.
• · Proficient may redeem the notes for cash on or after August 15, 2030, if the stock price exceeds 130% of the conversion price for a specified period.
• · Proficient may also redeem the notes if outstanding principal is less than 10% of the initial aggregate principal amount.
• · Upon a fundamental change, Proficient must offer to repurchase the notes at par plus accrued interest.
• · Capped call transactions have an initial cap price of $8.93 per share and are expected to expire starting May 18, 2033.
• · Option counterparties may engage in hedging activities that could affect the market price of PAL common stock or the notes.

14-08-2026

OPKO Health filed an 8-K on August 14, 2026, reporting entry into a material definitive agreement (Item 1.01) and creation of a direct financial obligation (Item 2.03). The filing does not disclose the counterparty, transaction value, or specific terms, making it impossible to assess financial impact or strategic importance. No other material events, financial metrics, or scheduled events are mentioned.

• · Filing date: August 14, 2026
• · AccNo: 0001193125-26-352370
• · Size: 161 KB
• · No exhibits or financial statements were included in the summary.

14-08-2026

Thunder Bridge Capital Partners V, Ltd. filed an 8-K on August 14, 2026, reporting multiple material events including entry into a definitive agreement (Item 1.01), unregistered sales of equity (Item 3.02), director/officer departures and appointments (Item 5.02), amendments to charter/bylaws (Item 5.03), and other events (Item 8.01). The filing is multi-item but lacks specific financial details, transaction values, or named parties, making it impossible to assess the magnitude or direction of the events. No quantitative data, guidance, or scheduled events were disclosed.

• · Filing includes Item 9.01 (Financial Statements and Exhibits), but no exhibits or financial statements were provided in the summary.
• · The filing is 2 MB in size, suggesting detailed exhibits may be attached but not summarized.
• · No specific names of departing or appointed directors/officers were disclosed in the summary.
• · No details on the nature of the material definitive agreement (Item 1.01) were provided.
• · No information on the number of shares or pricing for the unregistered equity sales (Item 3.02).

14-08-2026

The filing reports VICI Properties L.P.'s entry into a material definitive agreement (Item 1.01) and creation of a direct financial obligation (Item 2.03) on August 14, 2026. However, no specific financial terms, transaction size, or strategic details are disclosed in the summary provided. The filing also includes Item 9.01 (Financial Statements and Exhibits), but no quantitative data, period-over-period comparisons, or forward-looking guidance are available from the given text.

• · Filed on August 14, 2026, within required 4 business hours of the event.
• · Multi-item filing covering Items 1.01, 2.03, and 9.01.
• · No specific dollar value, share count, or percentage changes disclosed in the provided summary.

14-08-2026

Delek Logistics Partners, LP entered into an underwriting agreement on August 12, 2026 to sell 4,000,000 common units at $50.00 per unit, with a 30-day option for underwriters to purchase up to an additional 600,000 units. The offering is being conducted under an existing shelf registration statement. No period-over-period comparisons are available as this is a one-time capital markets transaction.

• · The underwriting agreement includes customary representations, warranties, and covenants, as well as indemnification provisions.
• · The offering is made under a Form S-3 registration statement (File No. 333-278939) originally filed on April 26, 2024 and declared effective on May 7, 2024.
• · The prospectus supplement for this offering is dated August 12, 2026, supplementing a prior prospectus supplement dated October 8, 2024.

14-08-2026

EDAP TMS SA entered into an underwriting agreement with TD Securities (USA) LLC and Mizuho Securities USA LLC for an underwritten public offering of 8,425,000 American Depositary Shares (ADSs) at $4.75 per ADS, expected to close on August 14, 2026. Net proceeds are expected to be approximately $37.1 million, which will be used for operating costs, capital expenditures, and general corporate purposes. This capital raise provides additional liquidity but will dilute existing shareholders.

• · The offering is made under a shelf registration statement on Form S-3 (File No. 333-294597), declared effective by the SEC on March 31, 2026.
• · Underwriters have a 30-day option to purchase up to 1,263,750 additional ADSs.
• · Executive officers and directors of the Company are subject to a 90-day lock-up period, waivable by the representatives.

14-08-2026

Accelerant Holdings (ARX) has entered into a definitive merger agreement to be acquired by Cherry Tree BidCo, an entity affiliated with Thoma Bravo Discover Fund V, L.P., in an all-cash transaction. The merger is expected to close in the second half of 2026, subject to shareholder approval, regulatory clearances, and other customary conditions. The transaction will result in Accelerant becoming a privately held company.

• · The merger agreement was dated August 13, 2026, and filed on August 14, 2026.
• · The transaction is structured as a merger of Merger Sub into Accelerant, with Accelerant surviving as a wholly owned subsidiary of Parent.
• · The Company Board established a Special Committee of independent and disinterested directors to evaluate the transaction.
• · The merger is subject to approval by Accelerant's shareholders, regulatory approvals under Antitrust Laws and Insurance Laws, and other customary conditions.
• · The agreement includes a 'go-shop' period, allowing Accelerant to solicit alternative acquisition proposals.
• · Thoma Bravo has provided an equity commitment letter and a guarantee to support the financing of the transaction.

14-08-2026

Dominari Holdings entered into inducement agreements with holders of Series A warrants to reduce market overhang, offering either a reduced cash exercise price of $2.20 per share or a 5:1 exchange for common stock. The company expects gross proceeds of approximately $2.9 million from cash exercises and to issue about 115,000 shares from exchanges, leaving approximately 1.2 million warrants outstanding.

• · Original exercise price of Existing Warrants was $3.72 per share, reduced to $2.20 per share under Option A.
• · Option B exchange ratio is 5:1, meaning one share of common stock for every five shares underlying exchanged warrants.
• · Exchange Shares issued under Section 3(a)(9) exemption from registration.
• · Existing Warrants were originally issued on February 14, 2025.
• · Registration statement on Form S-3 (No. 333-286648) declared effective on April 25, 2025.

14-08-2026

Zoomcar Holdings announced voting results from its 2026 Annual Meeting, where stockholders approved all six proposals, including an increase in authorized shares from 250,000,000 to 1,990,000,000, the issuance of up to 509,192,089 shares in connection with a warrant exchange offer, a reverse stock split (ratio between 1:2 and 1:800), and a 1,000,000 restricted share grant to Chairman Uri Levine. The Authorized Share Increase was filed and became effective on August 13, 2026. While the approvals passed with strong majorities, the company faces potential dilution and ongoing risks related to its capital structure and OTC trading.

• · The reverse stock split ratio will be between 1-for-2 and 1-for-800, with timing and ratio at Board discretion.
• · The Company filed a Certificate of Amendment with the Delaware Secretary of State effecting the Authorized Share Increase, effective August 13, 2026.
• · The Offer to Exchange is being made pursuant to a Schedule TO filed January 23, 2026, as amended.
• · The Company's common stock trades on OTCQB under ticker ZCAR.

14-08-2026

Oportun Financial Corp announced the appointment of Scott Scheirman to its Board of Directors as an independent Director, effective August 11, 2026. Scheirman, a former CEO of CPI Card Group and former CFO of Western Union, will chair the Audit & Risk Committee and serve on the Compensation & Leadership Committee, expanding the board to eight members. The filing highlights the company's commitment to board refreshment but does not include any financial results or period-over-period comparisons.

• · Scott Scheirman retired as President and CEO of CPI Card Group in January 2024 after serving since October 2017.
• · Scheirman previously co-founded JKL Ventures LLC and served as EVP and CFO of Western Union.
• · He began his career at Ernst & Young LLP and holds a B.S. in Business Administration (Accounting) from the University of Northern Colorado.
• · Oportun has saved members more than $2.5 billion in interest and fees since inception.
• · Members set aside an average of more than $1,800 annually.

14-08-2026

Fermi Inc. appointed Lee McIntire as CEO effective August 11, 2026, with an annual base salary of $750,000, a target bonus of 100% of base salary, and a $3,000,000 restricted stock unit grant under the 2025 LTIP. The appointment follows the company's conversion from Fermi LLC to Fermi Inc. in June 2025. No prior period financial data is provided, so no period-over-period comparisons are available.

• · Mr. McIntire will continue to serve as a director without additional compensation.
• · The RSU award cliff vests on the first anniversary of the grant date, subject to continued employment.
• · Accelerated vesting occurs upon 60 days after successor CEO appointment, change in control without award assumption, termination without cause within 12 months post-change in control, or death/disability.
• · Severance includes unpaid base salary, accrued vacation, vested benefits, and unreimbursed expenses; plus annual bonus for prior year if termination due to death or disability.
• · Mr. McIntire is required to be present at a company facility at least three days per week.

14-08-2026

Liberty Star Uranium & Metals Corp. entered into a Securities Purchase Agreement with 1800 Diagonal Lending LLC on August 11, 2026, issuing a convertible promissory note with an aggregate principal amount of $73,700. The note carries an 8% interest rate, a 10% original issue discount, and matures on May 30, 2027. This financing provides modest capital but increases the company's debt and potential dilution from conversion into common stock.

• · The note matures on May 30, 2027.
• · The note is convertible into shares of the company's common stock.
• · The Securities Purchase Agreement and Note are filed as Exhibits 3.87 and 3.88 to the 8-K.

14-08-2026

Texas Mineral Resources Corp. filed an 8-K on August 14, 2026, reporting the adoption of an amended and restated certificate of incorporation in connection with a merger completed on August 7, 2026. The new certificate authorizes only 100 shares of common stock, indicating a significant corporate restructuring. No financial details are provided in this filing.

• · The amended certificate of incorporation was adopted in connection with the first merger on August 7, 2026.
• · The company is now incorporated in Delaware with registered office at 1521 Concord Pike, Suite 201, Wilmington, DE 19803.
• · The certificate includes provisions for director exculpation and indemnification to the fullest extent permitted under Delaware law.

14-08-2026

Amcor plc announced the resignation of its independent auditor PricewaterhouseCoopers AG, Switzerland (PwC Switzerland) and the appointment of PricewaterhouseCoopers LLP, US (PwC US), effective August 14, 2026. The change was requested by the Audit Committee due to Amcor's status as a US domestic reporting company and its growing US operations. No adverse opinions, disagreements, or reportable events occurred during the fiscal years ended June 30, 2026 and 2025.

• · PwC Switzerland had served as Amcor's independent auditor since 2019.
• · PwC US will begin with the transition fiscal year ending December 31, 2026, including reviews of the interim period ending September 30, 2026.
• · PwC Switzerland will continue to support residual statutory filings for the fiscal year ending June 30, 2026.
• · PwC Switzerland's reports for fiscal years 2026 and 2025 contained no adverse opinion, disclaimer, or qualification.
• · No disagreements or reportable events occurred with PwC Switzerland during those fiscal years.
• · Amcor did not consult PwC US on any accounting, auditing, or financial reporting matters prior to the appointment.

14-08-2026

Cable One, Inc. announced the appointment of Heather McCallion as Chief Operating Officer, effective August 24, 2026. McCallion brings over 25 years of executive experience from WOW! and Breezeline. The filing contains no financial data or period-over-period comparisons, so no quantitative performance metrics are available.

• · McCallion's expected start date is August 24, 2026.
• · She will oversee residential sales and marketing, customer experience, customer care, field operations, and digital transformation.
• · Her most recent role was Chief Experience Officer at WOW!.
• · Prior roles at Breezeline included Vice President, General Manager of Florida markets and Vice President of New Business & Business Transformation.

14-08-2026

RF Acquisition Corp II (RFAIR) shareholders approved an extension of the deadline to complete a business combination from August 15, 2026 to February 15, 2027, allowing up to six one-month extensions. Each extension requires a $75,000 deposit into the trust account and five days' advance notice (two days for the first extension). The company also amended its trust agreement to reflect these changes.

• · The original trust agreement was dated May 16, 2024 and first amended on November 10, 2025.
• · The special meeting was held on August 12, 2026.
• · The company forfeited its right to withdraw up to $100,000 of interest to pay liquidation and dissolution expenses.
• · The extension letter must be sent to Continental Stock Transfer & Trust Company at 1 State Street, 30th Floor, New York, NY 10004.

14-08-2026

On August 11, 2026, James C. Neary resigned as a Class I director of Sotera Health Company, effective August 13, 2026, with no disagreement with the company's operations, policies, or practices. In response, the Board reduced its size from twelve to eleven directors. This is a routine board change with no financial impact.

• · Resignation effective August 13, 2026
• · Board size fixed at eleven directors as of the Effective Date

14-08-2026

Neumora Therapeutics reported Q2 2026 financial results with a net loss of $43.1 million, improved from a $52.7 million loss in Q2 2025, driven by lower R&D and G&A expenses. The company appointed Joshua Pinto, Ph.D., as CEO and Doron Sagman, M.D., as CMO, while Paul L. Berns became Executive Chair. Cash and equivalents stood at $116.8 million, expected to fund operations into Q3 2027, but the company has no approved products and continues to burn cash with no revenue.

• · Net loss per share improved to $(0.23) in Q2 2026 from $(0.33) in Q2 2025.
• · Total operating expenses decreased to $42.2M in Q2 2026 from $54.0M in Q2 2025.
• · Interest income fell to $0.9M in Q2 2026 from $2.3M in Q2 2025.
• · Interest expense increased to $1.8M in Q2 2026 from $0.4M in Q2 2025.
• · Total assets declined to $125.2M as of June 30, 2026 from $191.0M at year-end 2025.
• · Stockholders' equity dropped to $44.5M from $103.9M at December 31, 2025.
• · No revenue was reported; the company remains pre-commercial.

14-08-2026

Aptera Motors Corp. expanded its board from four to five members and appointed Wellington J. Reiter as an independent director, effective August 11, 2026. Mr. Reiter also joined the Audit Committee. He received a total of 210,045 RSUs under the 2025 Omnibus Equity Incentive Plan, including a fully vested annual retainer of 22,831 RSUs ($50,000), a fully vested committee retainer of 4,566 RSUs ($10,000), and a long-term incentive grant of 182,648 RSUs ($400,000) vesting over four years. No negative or flat metrics are present in this filing.

• · The board size increased from four to five members.
• · Mr. Reiter was appointed to the Audit Committee.
• · The long-term incentive RSUs vest 25% per year over four years.
• · No arrangements or understandings exist between Mr. Reiter and others regarding his selection.
• · No transactions requiring disclosure under Item 404(a) of Regulation S-K were identified.

14-08-2026

Wheeler Real Estate Investment Trust, Inc. appointed Jason F. Simone as Chief Financial Officer, effective August 10, 2026. Mr. Simone, who has been with the company since 2022 and most recently served as Director of Corporate Finance, succeeds the prior CFO. No new compensatory arrangements were entered into in connection with the appointment.

• · Mr. Simone, age 48, has been employed by the Company since 2022 in various positions of increasing responsibility, most recently as Director of Corporate Finance.
• · Prior to joining Wheeler, Mr. Simone was employed by Cedar Realty Trust, Inc., now a wholly-owned subsidiary of the Company.
• · There is no arrangement or understanding between Mr. Simone and any other person regarding his appointment, and he has no family relationships with any directors or executive officers.
• · No new compensatory arrangements were entered into with Mr. Simone in connection with his appointment.

14-08-2026

Space Exploration Technologies Corp. (SpaceX) completed its acquisition of Anysphere, Inc. (Cursor) on August 14, 2026, through a merger. The total consideration included approximately 389.3 million shares of SpaceX Class A common stock for Cursor's outstanding equity, based on an implied equity value of $60.0 billion, plus additional shares and equity awards for Cursor's RSUs and stock options. The acquisition was funded entirely with stock, with no cash component disclosed.

• · The merger was structured as a reverse triangular merger with X67 Inc., a wholly owned subsidiary of SpaceX, merging into Cursor.
• · The price per share of SpaceX Class A common stock used for the conversion was based on the volume-weighted average closing price over the seven consecutive trading days immediately preceding the closing.
• · The issuance of shares to Cursor stockholders was exempt from registration under Section 4(a)(2) of the Securities Act as a transaction not involving a public offering.
• · The Merger Agreement was originally filed as Exhibit 10.1 to SpaceX's Form 8-K on June 16, 2026.

14-08-2026

Ultra Clean Holdings, Inc. (UCTT) entered into a Sales Agreement on August 14, 2026, with UBS Securities LLC, Barclays Capital Inc., Craig-Hallum Capital Group LLC, and Oppenheimer & Co. Inc. to establish an at-the-market (ATM) offering program for up to $400 million of its common stock. The company is not obligated to sell any shares and may suspend sales at any time, while the sales agents will receive a commission of up to 3.0% of gross proceeds. This filing is a routine capital markets activity and does not reflect any operational or financial performance metrics.

• · The ATM offering is made under an automatic shelf registration statement on Form S-3 (Registration No. 333-278195) initially filed on March 25, 2024.
• · The company may sell shares through ordinary brokers' transactions, to or through a market maker, on The Nasdaq Global Select Market, in the over-the-counter market, or in privately negotiated transactions.
• · The company has agreed to reimburse the sales agents for certain specified expenses and provide customary indemnification and contribution rights.
• · The Sales Agreement may be terminated by the company at any time or by any sales agent with respect to itself.

14-08-2026

Labcorp Holdings Inc. announced the resignation of Megan D. Bailey as EVP and President, Central Laboratories and International, effective September 4, 2026. Concurrently, Brian J. Caveney, M.D. will expand his role to EVP and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, adding oversight of Central Laboratories to his existing Early Development Research Laboratories responsibilities, effective September 1, 2026. The filing contains no financial data or period-over-period comparisons.

• · Megan Bailey's resignation is effective September 4, 2026.
• · Brian Caveney's expanded role is effective September 1, 2026, two days before Bailey's departure.
• · The new combined business unit is named Biopharma Laboratory Services, encompassing both Early Development Research Laboratories and Central Laboratories.

14-08-2026

Farmer Mac announced the appointment of Nader Pasdar as Executive Vice President – Chief Business Officer, effective August 17, 2026. Pasdar brings over 25 years of experience in agricultural finance and capital markets, previously serving as CEO of Rabo Securities and Managing Director at Rabobank. This appointment follows Zachary N. Carpenter's transition to President and CEO in July 2026.

• · Mr. Pasdar will report directly to Zachary N. Carpenter.
• · Mr. Pasdar was a founding member of Rabobank's loan syndication team and contributed to hundreds of lead-arranged financings.
• · Mr. Pasdar holds an M.B.A. in finance from Boston University and a B.S. in economics from Temple University.

14-08-2026

Dyadic International announced a registered direct offering and concurrent private placement expected to raise approximately $2.9 million in gross proceeds. The offering includes 3,625,000 shares of common stock at $0.795 per share and warrants to purchase 3,625,000 shares at an exercise price of $0.84 per share. The company plans to use net proceeds for general corporate purposes and working capital.

• · The offering is expected to close on or about August 14, 2026, subject to customary closing conditions.
• · The registered direct offering is made under an effective shelf registration statement on Form S-3 (No. 333-273829) declared effective by the SEC on August 25, 2023.
• · The private placement warrants are not registered under the Securities Act and are offered only to accredited investors.
• · The company has agreed to file registration statements covering the resale of the common stock and shares issuable upon exercise of the warrants.

14-08-2026

Lifeward reported Q2 2026 revenue of $6.6M, up 16% YoY, driven by a 25% increase in AlterG products and a 13% rise in ReWalk sales. However, gross margin declined to 41% from 44% due to tariffs and foreign exchange, and net loss widened to $11.5M from $6.6M largely on non-cash warrant charges. The company also announced the departure of CFO Almog Adar and three board members, while strengthening its balance sheet to a proforma cash balance of ~$11M.

• · MyoCycle FES bike sales were flat at $0.1M, unchanged from Q2 2025.
• · Gross margin declined to 41% from 44% due to higher tariffs, FX fluctuations, and a 4% revenue sharing expense from the Oramed transaction.
• · Adjusted operating expenses (non-GAAP) increased 8% to $6.5M, driven by $0.7M in Oratech clinical trial costs.
• · Adjusted operating loss (non-GAAP) widened to $3.8M from $3.5M.
• · Net loss increased to $11.5M from $6.6M, primarily due to non-cash fair value charges on warrant and derivative liabilities.
• · Adjusted net loss (non-GAAP) increased to $4.1M from $3.5M.
• · Cash balance improved to $9.4M as of June 30, 2026, from $2.2M at year-end 2025; proforma cash ~$11M including July proceeds.
• · An additional $5.6M in growth capital is available upon achieving a 150% increase in ReWalk sales or stock price of $13.80 for 10 consecutive trading days.
• · CFO Almog Adar will depart effective September 30, 2026; three board members (Chairman Bob Marshall, Mike Swinford, William Sigsbee) stepped down August 13, 2026.

14-08-2026

Skye Bioscience (SKYE) announced a definitive agreement to acquire Redx Pharma via a scheme of arrangement, creating Fibrx Therapeutics, a fibrosis-focused company led by Redx's management. The transaction includes ~$125 million in committed financings (PIPE of ~$68M, Series A of $36M, and a $22M equity line facility) to fund operations into 2029 and through the RXC008 Phase 2 topline data expected in H2 2028. However, Skye's legacy asset nimacimab was discontinued after a strategic review, and pre-transaction Skye shareholders will own only ~5.38% of the combined company, with CVRs providing potential future value from nimacimab monetization.

• · RXC008 has an open U.S. IND and FDA Fast Track designation (granted January 2026).
• · Phase 1 data for RXC008 showed favorable tolerability and no serious adverse events.
• · RXC007 completed a successful signal-searching Phase 2 program in IPF and is a candidate for partnering.
• · DDR inhibitor IND submission expected in 2027.
• · Skye discontinued the CBeyond trial and paused nimacimab development in Q2 2026.
• · Combined company expected to have ~934,235,920 fully diluted shares outstanding.
• · Transaction expected to close in Q4 2026, subject to shareholder and regulatory approvals.
• · Skye shareholders will receive one CVR per share for 90% of net proceeds from nimacimab monetization within 12 months post-closing.
• · Certain Redx shareholders will receive CVRs for 100% of net proceeds from legacy/partnered assets over 15 years.
• · Combined company to be headquartered in Alderley Park, U.K.

14-08-2026

Isabella Bank Corporation entered into a Supplemental Executive Retirement Plan (SERP) participation agreement with CFO Gerald J. Ritzert on August 11, 2026. The agreement provides for eight annual credits totaling $300,000, with early retirement at age 55 and normal retirement at age 65, replacing the default payment form with five annual installments. This is a routine executive compensation arrangement with no negative or flat performance metrics to report.

• · The Participation Agreement replaces the Plan's default form of payment with five annual installments.
• · The agreement is qualified by reference to Exhibit 10.1.

14-08-2026

TCW Specialty Lending LLC entered into an Organizational and Offering Expense Reimbursement Agreement with its adviser, TCW Asset Management Company LLC, on August 12, 2026. Under the agreement, the company will reimburse the adviser for organizational and offering expenses that exceed 10 basis points of aggregate commitments. This is a routine administrative arrangement with no financial impact disclosed.

• · The agreement was entered into on August 12, 2026, and filed as Exhibit 10.1.
• · The reimbursement covers organizational expenses and offering expenses exceeding 10 basis points of aggregate commitments.

14-08-2026

Heron Therapeutics filed an 8-K on August 14, 2026, reporting entry into a material definitive agreement (Item 1.01) and material modifications to security holders' rights (Item 3.03). The filing does not disclose the counterparty, transaction value, or specific financial terms, limiting quantitative assessment. No financial statements or operational metrics were provided, and no scheduled events were announced. The filing appears to be a mandatory disclosure, but the lack of detail prevents a clear directional view.

• · Filing size: 231 KB
• · AccNo: 0001193125-26-352403
• · Filed on August 14, 2026
• · No financial statements or exhibits were included in the filing summary
• · No counterparty or transaction value disclosed

14-08-2026

StoneBridge Acquisition II Corp entered into a waiver with Scieniti LLC, an affiliate of its sponsor, to irrevocably waive monthly administrative service fees of $10,000 from October 1, 2025, until the earlier of its initial business combination or liquidation. This reduces cash burn and simplifies financial obligations during the SPAC's search for a merger target.

• · The waiver was signed on August 10, 2026, and filed on August 14, 2026.
• · The original Administrative Services Agreement was entered into on September 30, 2025.
• · The waiver covers all periods from October 1, 2025, through the earlier of the initial business combination or liquidation.

14-08-2026

HCW Biologics Inc. disclosed on August 10, 2026 that its previously issued unaudited financial statements for Q1 2026 should no longer be relied upon due to a material error in EPS calculation. The company overstated basic and diluted EPS by $0.80 per share (reporting $2.19 instead of the correct $1.39) by misapplying the two-class method for allocating undistributed earnings. A material weakness in internal controls over complex warrant instruments was identified, and remediation measures are underway.

• · The error was identified by the Audit Committee in consultation with management and Crowe LLP.
• · The restatement will affect the unaudited condensed financial statements for the three months ended March 31, 2026, and related disclosures.
• · A material weakness existed related to ineffective operation of technical accounting review control over complex warrant instruments and financing transactions.
• · The company intends to file an amended Form 10-Q/A and update applicable registration statements.
• · Previously furnished press releases and earnings communications for Q1 2026 should no longer be relied upon.

14-08-2026

AppTech Payments Corp. has entered into a $500,000 promissory note with the Suzanne D. Lord Spousal Estate Reduction Trust, bearing 9% annual interest and maturing in 90 days (November 8, 2026). The proceeds are designated for short-term working capital and general corporate purposes. The note is unsecured and contains standard default provisions, including bankruptcy and material breach.

• · The note is governed by California law and includes a 10-business-day cure period for material breaches.
• · Prepayment is allowed at any time without premium or penalty, but must include accrued interest.
• · The lender is a trust associated with Albert L. Lord, Jr., not a financial institution.

14-08-2026

Prestige Consumer Healthcare Inc. announced the retirement of Jeffrey Zerillo as Senior Vice President, Operations, effective August 14, 2026. The departure is a routine officer retirement with no disclosed financial impact or replacement details.

• · Jeffrey Zerillo's retirement is effective August 14, 2026.
• · No successor or interim appointment has been announced.

14-08-2026

PSQ Holdings, Inc. entered into a Securities Purchase Agreement on August 13, 2026, with certain purchasers in a private placement. The company issued unregistered equity securities, and the proceeds are intended for general corporate purposes. No specific financial terms or amounts were disclosed in this filing.

• · The Securities Purchase Agreement was dated August 13, 2026.
• · The filing covers Items 1.01 (Material Agreement Entry), 3.02 (Unregistered Sales of Equity Securities), and 9.01 (Exhibits).
• · The company disclaimed any obligation to update forward-looking statements.

14-08-2026

Vuzix Corporation entered into a new Open Market Sales Agreement with Jefferies LLC to sell up to $100,000,000 of its common stock in an at-the-market offering. This replaces a prior agreement from February 2024. Jefferies will receive a 3.0% commission on gross proceeds.

• · The Sales Agreement is filed as Exhibit 1.1 to the 8-K.
• · The offering is made under Vuzix's effective S-3 registration statement (File No. 333-276997) and a prospectus supplement dated August 14, 2026.
• · The prior Sales Agreement with Jefferies (dated February 9, 2024) is replaced and no further sales will occur under it.
• · The agreement terminates upon the earlier of sale of all shares or termination as permitted in the agreement.
• · Vuzix reimburses Jefferies for certain expenses and provides customary indemnification.
• · Legal opinion from Sichenzia Ross Ference Carmel LLP is attached as Exhibit 5.1.

14-08-2026

H&R Block Inc. filed an 8-K on August 14, 2026, disclosing a change in officers under Item 5.02. The filing does not specify the position, reason, or whether it is an appointment or resignation. No financial metrics, compensation details, or other quantitative data are provided. The event appears informational with no immediate directional impact, but the lack of detail warrants monitoring.

• · Filing date: August 14, 2026
• · Accession number: 0000012659-26-000028
• · File size: 138 KB
• · Sector: not specified
• · No specific officer name, position, or action (appointment/resignation) disclosed in the summary.

14-08-2026

Yi 'Faith' Tang resigned from the Board of Directors of Hawkins, Inc. effective August 13, 2026. The resignation was not due to any disagreement with the company's operations, policies, or practices.

14-08-2026

NewtekOne, Inc. filed an 8-K on August 14, 2026, reporting an officer change under Item 5.02. The filing does not disclose the specific officer, the nature of the change (appointment or resignation), the reason, or any financial details. Without these critical facts, the filing is purely informational with no material impact on investment thesis.

• · The filing was made on August 14, 2026, with accession number 0001628280-26-057098.
• · The filing size is 216 KB, but no specific officer name, title, or change type is disclosed in the summary.
• · No compensatory arrangements, financial metrics, or future events are mentioned.

14-08-2026

On August 6, 2026, Lewis Liu resigned as COO of Phoenix Motor Inc., effective immediately. He continues employment with a subsidiary. No financial impact or prior-period comparisons are provided.

• · Lewis Liu's resignation as COO was effective August 6, 2026.
• · His resignation does not affect his continued employment with a subsidiary of the company.

14-08-2026

Cencora, Inc. filed an 8-K on August 14, 2026, reporting an officer change under Item 5.02. The filing discloses the departure or appointment of a director or officer and related compensatory arrangements. No specific financial metrics, transaction values, or performance data are provided in the filing summary. The change appears to be a routine governance disclosure, but without details on the specific officer, reason, or timing, the materiality and market impact cannot be fully assessed.

• · Filing date: August 14, 2026
• · SEC Accession Number: 0001104659-26-097096
• · File size: 240 KB
• · Item 5.02 disclosure: Officer change and compensatory arrangements

14-08-2026

The filing reports the departure of Beauty Health Co's Chief Financial Officer, effective August 14, 2026, with no reason provided and no successor named. While the company has disclosed the change in compliance with SEC rules, the lack of explanation and absence of a succession plan raise governance concerns and signal potential instability.

• · The filing does not disclose the reason for the CFO's departure.
• · No interim or permanent successor has been appointed as of the filing date.
• · The departure is effective immediately (August 14, 2026).

14-08-2026

O'Reilly Automotive filed an 8-K on August 14, 2026, reporting the entry into a material definitive agreement under Item 1.01. The filing does not provide any financial specifics, transaction value, or detailed terms of the agreement, limiting a full quantitative assessment. No other items or financial data are disclosed, making this a single-item, likely voluntary disclosure with no immediate directional impact from the filing itself.

14-08-2026

Power Integrations Inc. (POWI) disclosed in an 8-K filing that Sunil Gupta, Senior Vice President of Operations, notified the company on August 11, 2026 of his resignation effective August 25, 2026. The filing explicitly states the resignation did not result from any disagreement with the company regarding its operations, policies, or practices. No financial impact, successor information, or quantitative data was provided in the filing.

• · Resignation effective date: August 25, 2026.
• · No disagreement was cited as the reason for departure.
• · The resignation was notified on August 11, 2026, filed on August 14, 2026.

14-08-2026

NewAmsterdam Pharma appointed Robert W. Gunning as principal accounting officer, effective August 10, 2026, succeeding Louise Kooij whose departure was previously announced. Mr. Gunning will receive a base salary of $375,000 per year, a target bonus of 30% of base salary, and equity awards of 3,200 restricted stock units and a stock option for 14,000 ordinary shares. The filing does not contain any financial results or period-over-period comparisons.

• · Mr. Gunning previously served as Interim Controller at Altimmune from April 2026 to July 2026.
• · He was Vice President Finance and Corporate Controller at Y-mAbs Therapeutics from April 2022 to April 2026.
• · He holds a BBA from Pace University.
• · The equity awards are granted under the company's 2024 Inducement Plan.
• · Mr. Gunning has no family relationships with directors or executive officers and no material interest in any existing or proposed transaction requiring disclosure.

14-08-2026

Momentus Inc. dismissed Frank, Rimerman + Co. LLP as its independent auditor on August 11, 2026, and appointed Baker Tilly US, LLP as its new auditor effective August 12, 2026. The change was approved by the Audit Committee and was not due to any disagreements on accounting principles, though the prior auditor's 2024 report included a going concern qualification. The company had previously disclosed and subsequently remediated a material weakness in internal controls as of December 31, 2025.

• · Frank, Rimerman's report for FY2024 included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• · The company identified a material weakness in internal control over financial reporting related to misclassification errors, which was remediated as of December 31, 2025.
• · No disagreements with Frank, Rimerman on accounting principles or audit scope occurred during the fiscal years 2024 and 2025 or the subsequent interim period.
• · The engagement agreement with Baker Tilly was executed on August 12, 2026.

14-08-2026

Byrna Technologies appointed retired U.S. Army Brigadier General Rose Lopez Keravuori to its Board of Directors, effective August 10, 2026, succeeding Emily Rooney who resigned the same day. Keravuori also joined a newly formed Enterprise Risk Management Committee alongside Board Chair TJ Kennedy, independent director Adam Roth, and CEO Conn Davis. The appointment brings extensive leadership in strategic operations, crisis management, and risk mitigation, supporting Byrna's expansion across consumer, professional security, and international markets.

• · Keravuori served as director of intelligence for U.S. Africa Command until her retirement in 2025.
• · She holds a directorship certification from NACD (NACD.DC) and is a Qualified Risk Director (QRD) through the DCRO Institute.
• · She is a graduate of the United States Military Academy at West Point and holds an MBA from Cameron University.
• · The Enterprise Risk Management Committee includes three independent directors and the CEO.

14-08-2026

Crescent Private Credit Income Corp announced the resignation of President Raymond Barrios, effective August 10, 2026, with no disagreement with management or the Board. The company appointed Eric Hall, who has served as CEO since 2023, as the new President effective August 11, 2026. Mr. Hall will continue as CEO and also serves as co-CEO, director, and chairman of an affiliate BDC and as a Managing Director at Crescent Capital Group LP.

• · Eric Hall has been CEO since 2023 and will continue in that role alongside the presidency.
• · Mr. Hall is a Managing Director at Crescent Capital Group LP, the parent of the company's investment adviser.
• · Prior to joining Crescent in 2007, Mr. Hall worked as a Financial Analyst in Lehman Brothers' Investment Banking Division.
• · Mr. Hall holds a B.A. in Business Economics from UCLA.

14-08-2026

Capital Bancorp Inc. dismissed Elliott Davis, PLLC as its independent auditor and engaged Crowe LLP for fiscal year 2026, citing the need for a larger firm with additional resources and industry specialization. The prior audit reports were unqualified, and no disagreements or reportable events occurred, except for a previously disclosed material weakness in internal controls. The change was approved by the Audit Committee and is effective as of August 14, 2026.

• · The dismissal of Elliott Davis and engagement of Crowe LLP were approved by the Audit Committee.
• · Elliott Davis's audit reports for fiscal years 2024 and 2025 were unqualified, with no adverse opinion or modification.
• · No disagreements or reportable events occurred during the relevant periods, except for a material weakness in internal control over financial reporting disclosed in the 2025 Form 10-K.
• · Crowe LLP had previously been engaged for valuation services related to the October 1, 2024 acquisition of Integrated Financial Holdings, Inc.
• · Elliott Davis provided a letter to the SEC dated August 14, 2026, agreeing with the disclosures, filed as Exhibit 16.1.